Managing Glipizide in Patients with Chronic Kidney Disease

Glipizide Dosing and Efficacy

Glipizide can be safely used in patients with an eGFR of 39 mL/min/1.73m² with appropriate dose adjustments, as it does not have active metabolites and does not increase the risk of hypoglycemia in patients with chronic kidney disease (CKD), according to the American Journal of Kidney Diseases 1
For patients with eGFR 30-44 mL/min/1.73m², initiate glipizide conservatively at 2.5 mg once daily and titrate slowly to avoid hypoglycemia, as recommended by Kidney International and Endocrine Reviews 2, 3
The American Journal of Kidney Diseases recommends avoiding first-generation sulfonylureas (chlorpropamide, tolazamide, tolbutamide) and glyburide altogether in patients with CKD 1

Monitor kidney function at least every 3-6 months in patients with eGFR <45 mL/min/1.73m², as suggested by Kidney International 5
Consider adding or switching to an SGLT2 inhibitor if eGFR ≥30 mL/min/1.73m², as these agents have proven kidney and cardiovascular benefits, according to Kidney International 4, 6
For patients with T2D and CKD, a treatment algorithm including metformin (if eGFR ≥30 mL/min/1.73m²) and an SGLT2 inhibitor is recommended as first-line therapy by Kidney International 6
If additional glucose-lowering is needed, a GLP-1 receptor agonist is preferred over continuing or increasing sulfonylurea doses, as recommended by Kidney International 4, 7